<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480077</url>
  </required_header>
  <id_info>
    <org_study_id>20061016-V2</org_study_id>
    <nct_id>NCT00480077</nct_id>
  </id_info>
  <brief_title>Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)</brief_title>
  <acronym>DOT-HF</acronym>
  <official_title>Diagnostic Outcome Trial in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DOT-HF trial is an international, prospective, multi-center, randomized, controlled
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed with a Control Arm in order to adequately study the effect of early
      intervention triggered by the OptiVol® Alert and/or SentryCheck™ Monitor/PatientLook™
      Indicator and evaluation using OptiVol® Fluid Status Monitoring with Cardiac Compass.
      OptiVol® Fluid Status Monitoring with Cardiac Compass features are available in the per
      Clinical Investigational Plan specified Medtronic products (CRT, CRT-D and ICD devices)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment rates
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention: in the access arm the patiens had programmmed the audible OptiVol Fliud status alert &quot;on&quot;. Control patienst had programmed the audible alert &quot;off&quot;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Combined End Point of All-cause Mortality or Heart Failure Hospitalization</measure>
    <time_frame>14.9 ± 5.4 months</time_frame>
    <description>Number of participants with a combined end point of all-cause mortality or heart failure hospitalization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Access Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HF subjects managed with standard clinical assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )</intervention_name>
    <description>OptiVol® Fluid status Monitoring with Cardiac Compass</description>
    <arm_group_label>Access Arm</arm_group_label>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>OptiVol® audible alert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of both genders with mild to severe HF as defined as NHYA Class II to IV who
             also have an indication for device implant according to ESC/AHA guidelines as well as
             having a HF hospitalization or Emergency Department visit necessitating therapy within
             the past 12 months and who meet all inclusion criteria and no exclusion criteria, are
             eligible for this study.

        Exclusion Criteria:

          -  Subject is post heart transplant or actively listed on the transplant list and
             reasonable probability (as defined by investigator) of undergoing transplantation in
             the next year

          -  Subject received a coronary artery bypass graft or valve surgery in last 90 days

          -  Subject with a myocardial infarction (MI) in the last 40 days.

          -  Subject's life expectancy is less than one year in the opinion of the physician

          -  Subject has severe Chronic Obstructive Pulmonary Disease (COPD), as determined by
             physician and documented in medical records

          -  Subject is listed for valve replacement/valve repair

          -  Subject has severe, primary pulmonary hypertension as determined by physician and
             documented in medical records

          -  Subject with serum creatinine ≥ 2.5 mg/dL measured within 14 days prior to enrolment

          -  Subject on chronic renal dialysis

          -  Subject on continuous or uninterrupted (≥ 2 stable infusions per week) infusion
             (inotropic) therapy for HF

          -  Subject has complex and uncorrected Congenital Heart Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. D.J. van Veldhuisen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Groningen University Hospital, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. med. M. Borggrefe</last_name>
    <role>Study Chair</role>
    <affiliation>Ruprecht-Karls-Universität Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. V. Conraads</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. C.M. Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital, Shatin, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. F. Braunschweig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. J. Kautzner</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKEM- Klinika Kardiologie, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. G. Jondeau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bichat Claude Bernard, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. M.R. Cowie</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart &amp; Lung Institute, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. R. Muñoz-Aguilera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañon, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. I. Ford</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robertson Center for Biostatistics, Scotland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. M Lunati</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Niguarda Ca' Granda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Bakken Research Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 GW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, Kautzner J, Aguilera RM, Lunati M, Yu CM, Gerritse B, Borggrefe M; DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011 Oct 18;124(16):1719-26. doi: 10.1161/CIRCULATIONAHA.111.043042. Epub 2011 Sep 19.</citation>
    <PMID>21931078</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <results_first_submitted>November 16, 2017</results_first_submitted>
  <results_first_submitted_qc>February 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2019</results_first_posted>
  <last_update_submitted>February 15, 2019</last_update_submitted>
  <last_update_submitted_qc>February 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, randomized, OptiVol® Fluid status monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Access Arm</title>
          <description>HF subjects managed with standard clinical assessment and using OptiVol® Fluid status monitoring with Cardiac Compass Report
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ) : OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>HF subjects managed with standard clinical assessment
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ) : OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>early exit</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Access Arm</title>
          <description>HF subjects managed with standard clinical assessment and using OptiVol® Fluid status monitoring with Cardiac Compass Report
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>HF subjects managed with standard clinical assessment
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="335"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>patient age and SD is similar between the 2 arms</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10"/>
                    <measurement group_id="B2" value="64" spread="10"/>
                    <measurement group_id="B3" value="64" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QRS duration</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142" spread="39"/>
                    <measurement group_id="B2" value="143" spread="36"/>
                    <measurement group_id="B3" value="142" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="5"/>
                    <measurement group_id="B2" value="27" spread="4"/>
                    <measurement group_id="B3" value="28" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA functional class</title>
          <description>Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20 100 m).Comfortable only at rest.
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA functional class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA functional class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA functional class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA functional class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="7"/>
                    <measurement group_id="B2" value="25" spread="7"/>
                    <measurement group_id="B3" value="25" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of device implanted</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CRT-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Combined End Point of All-cause Mortality or Heart Failure Hospitalization</title>
        <description>Number of participants with a combined end point of all-cause mortality or heart failure hospitalization</description>
        <time_frame>14.9 ± 5.4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Access Arm</title>
            <description>HF subjects managed with standard clinical assessment and using OptiVol® Fluid status monitoring with Cardiac Compass Report
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>HF subjects managed with standard clinical assessment
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Combined End Point of All-cause Mortality or Heart Failure Hospitalization</title>
          <description>Number of participants with a combined end point of all-cause mortality or heart failure hospitalization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary end point of the study, all-cause death or hospitalization for heart failure, was analyzed on a time-to-first-event basis with the log-rank test. The hazard ratio (HR) associated with allocation to the access arm relative to control was estimated with corresponding 95% confidence interval (CI) by fitting a Cox proportional hazards model containing the treatment group as a categorical factor.</non_inferiority_desc>
            <p_value>0.063</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>mean follow up period (months): 14.9 +/- 5.4</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Access Arm</title>
          <description>HF subjects managed with standard clinical assessment and using OptiVol® Fluid status monitoring with Cardiac Compass Report
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>HF subjects managed with standard clinical assessment
Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ): OptiVol® Fluid status Monitoring with Cardiac Compass</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="57" subjects_affected="39" subjects_at_risk="168"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lead Dislodgement</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director CRDM</name_or_title>
      <organization>Medtronic Bakken Research Center</organization>
      <phone>31-43-3566813</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

